Information Letter on Leqvio 284 mg solution for injection in a pre-filled syringe: Important information regarding instructions for use before injection
2023.12.21
Active substance: Inclisiran
The company Novartis informs about difficulties in moving the syringe plunger resulting in the inability to inject Leqvio. The issue occurs infrequently in the European Union (~ 0.01%). To ensure optimal use of Leqvio for patients and healthcare professionals, Novartis recommends removing the needle cap shortly before injection and using a new pre-filled syringe if the plunger cannot be moved after the needle has been inserted.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN